Principles of Minimal Residual Disease Detection for Hematopoietic Neoplasms by Flow Cytometry

被引:108
作者
Wood, Brent L. [1 ,2 ]
机构
[1] Univ Washington, Dept Lab Med & Pathol, Seattle, WA 98109 USA
[2] Seattle Canc Care Alliance, Seattle, WA USA
关键词
cytometry; leukemia; residual; minimal; monitoring; ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; RELAPSE RISK; IMMUNOPHENOTYPIC MODULATION; CLINICAL-SIGNIFICANCE; INDUCTION THERAPY; BONE-MARROW; T-CELL; CHILDHOOD; REMISSION;
D O I
10.1002/cyto.b.21239
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Flow cytometry has become an indispensible tool for the diagnosis and classification of hematopoietic neoplasms. The ability to rapidly distinguish cellular subpopulations via multiparametric assessment of quantitative differences in antigen expression on single cells and enumerate the relative sizes of the resulting subpopulations is a key feature of the technology. More recently, these capabilities have been expanded to include the identification and enumeration of rare subpopulations within complex cellular mixtures, for example, blood or bone marrow, leading to the application for post-therapeutic monitoring or minimal residual disease detection. This review will briefly present the principles to be considered in the construction and use of flow cytometric assays for minimal residual disease detection including the use of informative antibody combinations, the impact of immunophenotypic instability, enumeration, assay sensitivity, and reproducibility. (C) 2015 International Clinical Cytometry Society
引用
收藏
页码:47 / 53
页数:7
相关论文
共 44 条
  • [21] Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring
    Langebrake, C
    Brinkmann, I
    Teigler-Schlegel, A
    Creutzig, U
    Griesinger, F
    Puhhnann, U
    Reinhardt, D
    [J]. CYTOMETRY PART B-CLINICAL CYTOMETRY, 2005, 63B (01) : 1 - 9
  • [22] Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group
    Loken, Michael R.
    Alonzo, Todd A.
    Pardo, Laura
    Gerbing, Robert B.
    Raimondi, Susana C.
    Hirsch, Betsy A.
    Ho, Phoenix A.
    Franklin, Janet
    Cooper, Todd M.
    Gamis, Alan S.
    Meshinchi, Soheil
    [J]. BLOOD, 2012, 120 (08) : 1581 - 1588
  • [23] Normalization of Bone Marrow Aspirates for Hemodilution in Flow Cytometric Analyses
    Loken, Michael R.
    Chu, Sung-Chao
    Fritschle, Wayne
    Kalnoski, Michael
    Wells, Denise A.
    [J]. CYTOMETRY PART B-CLINICAL CYTOMETRY, 2009, 76B (01) : 27 - 36
  • [24] Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
    Martinez-Lopez, Joaquin
    Lahuerta, Juan J.
    Pepin, Francois
    Gonzalez, Marcos
    Barrio, Santiago
    Ayala, Rosa
    Puig, Noemi
    Montalban, Maria A.
    Paiva, Bruno
    Weng, Li
    Jimenez, Cristina
    Sopena, Maria
    Moorhead, Martin
    Cedena, Teresa
    Rapado, Immaculada
    Victoria Mateos, Maria
    Rosinol, Laura
    Oriol, Albert
    Blanchard, Maria J.
    Martinez, Rafael
    Blade, Joan
    San Miguel, Jesus
    Faham, Malek
    Gracia-sanz, Ramon
    [J]. BLOOD, 2014, 123 (20) : 3073 - 3079
  • [25] Comparison of Cross-Platform Flow Cytometry Minimal Residual Disease Evaluation in Multiple Myeloma Using a Common Antibody Combination and Analysis Strategy
    Mathis, Stephanie
    Chapuis, Nicolas
    Borgeot, Jessica
    Maynadie, Marc
    Fontenay, Michaela
    Bene, Marie-Christine
    Guy, Julien
    Bardet, Valerie
    [J]. CYTOMETRY PART B-CLINICAL CYTOMETRY, 2015, 88 (02) : 101 - 109
  • [26] Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
    Paiva, Bruno
    Vidriales, Maria-Belen
    Cervero, Jorge
    Mateo, Gema
    Perez, Jose J.
    Montalban, Maria A.
    Sureda, Anna
    Montejano, Laura
    Gutierrez, Norma C.
    de Coca, Alfonso Garcia
    Heras, Natalia de las
    Mateos, Maria V.
    Lopez-Berges, Maria C.
    Garcia-Boyero, Raimundo
    Galende, Josefina
    Hernandez, Jose
    Palomera, Luis
    Carrera, Dolores
    Martinez, Rafael
    de la Rubia, Javier
    Martin, Alejandro
    Blade, Joan
    Lahuerta, Juan J.
    Orfao, Alberto
    Miguel, Jesus F. San
    [J]. BLOOD, 2008, 112 (10) : 4017 - 4023
  • [27] Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL
    Rawstron, A. C.
    Boettcher, S.
    Letestu, R.
    Villamor, N.
    Fazi, C.
    Kartsios, H.
    de Tute, R. M.
    Shingles, J.
    Ritgen, M.
    Moreno, C.
    Lin, K.
    Pettitt, A. R.
    Kneba, M.
    Montserrat, E.
    Cymbalista, F.
    Hallek, M.
    Hillmen, P.
    Ghia, P.
    [J]. LEUKEMIA, 2013, 27 (01) : 142 - 149
  • [28] Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study
    Rawstron, Andy C.
    Child, J. Anthony
    de Tute, Ruth M.
    Davies, Faith E.
    Gregory, Walter M.
    Bell, Sue E.
    Szubert, Alexander J.
    Navarro-Coy, Nuria
    Drayson, Mark T.
    Feyler, Sylvia
    Ross, Fiona M.
    Cook, Gordon
    Jackson, Graham H.
    Morgan, Gareth J.
    Owen, Roger G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (20) : 2540 - +
  • [29] Immaturity Associated Antigens Are Lost During Induction for T Cell Lymphoblastic Leukemia: Implications for Minimal Residual Disease Detection
    Roshal, Mikhail
    Fromm, Jonathan R.
    Winter, Stuart
    Dunsmore, Kimberly
    Wood, Brent L.
    [J]. CYTOMETRY PART B-CLINICAL CYTOMETRY, 2010, 78B (03) : 139 - 146
  • [30] Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing
    Salipante, Stephen J.
    Fromm, Jonathan R.
    Shendure, Jay
    Wood, Brent L.
    Wu, David
    [J]. MODERN PATHOLOGY, 2014, 27 (11) : 1438 - 1446